• Philip Timmerman (Janssen Research and Development for EBF) - Welcome to the conference

• Ian Wilson (AstraZeneca) - What You Can’t See Can Hurt You: Looking at Bioanalysis by LC-MS From the Outside
• John Pugh (University of Sheffield) - Elemental imaging via LA-ICP-MS - New oppertunities in the life sciences
• Robert Plumb (Waters) - High Sensitivity Analysis of Biotherapeutics Using Capillary LC
• Martyn Hemsley (Covance) - Considerations and Experiences in Developing Bioanalytical Assays for the Quantitative Determination of Oligonucleotides

• Albert Wolthuis (KCL) - The Blood Matrix: A Dynamic Mirror
• Achiel Van Peer (Janssen Research and Development) - Blood and Plasma: "A Magic Twin or Single in Human Pharmacokinetics ?"
• John Perkins (Advion BioServices) - Long Term Stability Issues Observed during Validation of an LC-MS/MS assay for Clopidogrel and Metabolites
• Ronald de Vries (Janssen Research and Development) - Analyte Instability Issues in Blood
• Achim Freisleben (Merck-Serono for EBF) - EBF Current Thinking on the Conduct of Whole Blood Stability

• Philip Timmerman (Janssen Research and Development for EBF and GBC) - GBC-Harmonization Initiative and EBF Perspective
• Jérôme Barré (afssaps) - EMA Perspective on Global Harmonization
• Rafael Barrientos (Magabi for ACBio) - South America perspective
• Daniel Tang (Frontage for BBDS and SBDS) - APAC Perspective on Global Harmonization
• Mark Arnold (Bristol Meyers Squibb for AAPS) - AAPS Perspective on Global Harmonization
• C.T. Viswanthan (FDA/CDER) - FDA Perspective on Global Harmonization - Not released for publication

Platinum Sponsor sessions

• Gary Harland (Waters) - Addressing The Challenge of Sensitivity and Metabolite Detection in Bioanalytical Studies
• Mauro Aiello (AB SCIEX) - Overcoming the Data Analysis Bottleneck with Next Generation Quantitative Software
• Pat Bennett (Thermo Scientific) - Future of the Triple Quadrupole:  What is Possible and what is Practical?
• Lester Taylor (Agilent) - Use of an Ion Funnel Triple Quadrupole LC/MS Instrument for HighSensitivity Quantitation
• Martin Nemansky (PRA International) - Comparison of various platforms for large molecule analysis - Introduction of the Imperacer® technology
• Iain Shaw (Quotient Bioresearch) - C14 enabled drug development

• Stefanie Fischmann (Abbott) - Comparison of Data from ECL and Hyphenated LC-MS Platforms on Quantitation of mAb from Serum Samples
• Fritz Poulsen (NovoNordisk) - Wash AlphaLISA - An Extension of the AlphaLISA/LOCI Technology
• Ronald Schmidt (Sanofi-Aventis) - Quantitative LC-MS/MS Analysis of Synthetic Insulins - Withdrawn
• Craig Stovold (Quotient Bioresearch) - Appliation of the Gyrolab to bioanalytical, pharmacodynamic and immunogenicity analysis in a regulated laboratory
• Birgit Jaitner (Novartis) - An approach to measure total drug levels in human serum samples while overcoming target interference

• Philip Timmerman (Janssen Research and Development for EBF) - EBF recommendation on Method Validation for Dried Blood Spots
• Julian Haynes (Pfizer) - Application of a Simple 2D-LC-MS/MS System to Control Ion Suppression Effects from DBS Samples
• Rohan Takur (Taylor Technology) - DBS and HRMS for in vivo Fast PK studies – The Value and Advantage for Pre-Clinical Studies

• Vincenzo Pucci (Merck & Co Inc) - Strategies for Reducing Phospholipid-based Matrix Effects in LC-ESI-MS Bioanalysis
• Curtis Sheldon (Celerion) - Haemolysed Sample Evaluation : A Variety of Issues for a Variety of Situations
• Carl-Johan Sennbro (Active Biotech for EBF) - Choice of Anticoagulant and Comparison of Counter-Ions - Results from Two EBF Surveys
• Tom Verhaeghe (Janssen Research and Development) - Matrix Effects in Practice : Sense and Nonsense of Internal Standard Response Acceptance Criteria 
• Magnus Knutsson (Ferring) - Experiences of Assessing Matrix Effects by Monitoring Internal Standard Response in Study Samples

• Susan Kirshner (FDA) - US FDA Draft Guidance on Immunogenicity Testing
• Arjen Companjen (Crucell for EBF) - The EBF Perspective on the FDA draft guidance on Assay Development for Immunogenicity Testing of Therapeutic Proteins
• Robin Thorpe (NIBSC) - European Guidance on Unwanted Immunogenicity of Biologicals
• Geoff Hale (Merck/Millipore) - The untility and futility of cut points for assessing unwanted immunogenicity - Not released for publication
• Janka Ryding (Ferring) - Case Study: Neutralization Assay Design and Qualification
• Andrea Kiessling (Novartis) - Integrated Approach of PK/PD/Immunogenicity Analysis

• Fabio Garofolo (Algorithme Pharma Inc.) - When and How Much do Anomalous Results Need to be Investigated?
• Silke Lüdtke (Boehringer-Ingelheim for EBF) - Handling of Anomalous Results in Europe – Feedback from EBF Survey
• Margarete Brudny-Kloeppel (Bayer Schering Pharma AG for EBF) - Case studies from EBF member companies

• Peter van Amsterdam (Abbott for EBF) - Update on New Organization
• Margarete Brudny-Kloeppel  (Bayer Schering Pharma AG for EBF) - Feedback from EBF 2010 Surveys and Activities

• Liesbeth Vereyken (Janssen Research and Development) - Challenges with Nucleoside Triphospate Method Development and Analysis during the Life Cycle of a HCV Program
• Mark Spengler (Chimera) - Using Ligang-Binding Assay Sensitivity for Improved Matrix Tolerance and Related Parameters by Tailored Sample Dilution.
• Anna Valeri (MHRA) - Biomarker Development: A Regulatory Perspective - Not released for publication
• Jan Moack (Slovak University of Technology, Bratislava) - Effective use of Combination of Lung Malignity Marker

• Philip Timmerman (Janssen Research and Development for EBF) - Closing Remarks